Search Results - Kenneth Emancipator

Refine Results
  1. 1
    In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins

    In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins by Kenneth Emancipator, György Csákó, Ronald J. Elin

    Published 1992
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

    Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1 by Marisa Dolled‐Filhart, Charlotte Roach, Grant Toland, Dave Stanforth, Malinka Jansson, Gregory M. Lubiniecki, Gary Ponto, Kenneth Emancipator

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

    Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer by Charlotte Roach, Nancy Zhang, Ellie Corigliano, Malinka Jansson, Grant Toland, Gary Ponto, Marisa Dolled‐Filhart, Kenneth Emancipator, Dave Stanforth, Karina Kulangara

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy

    PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy by Steffen Filskov Sorensen, Wei Zhou, Marisa Dolled‐Filhart, Jeanette Bæhr Georgsen, Zhen Wang, Kenneth Emancipator, Dianna Wu, Michael Busch-Sørensen, Peter Meldgaard, Henrik Hager

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue

    Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue by Marisa Dolled‐Filhart, Darren Locke, Tiffany Murphy, Frank Lynch, Jennifer H. Yearley, Dennis M. Frisman, Robert J. Pierce, Russell Weiner, Dianna Wu, Kenneth Emancipator

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer

    Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer by Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, Tricia Bal, Ezra E.W. Cohen, Kevin J. Harrington, Denis Soulières, Christophe Le Tourneau, Lisa Licitra, Barbara Burtness, Ramona F. Swaby

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

    Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer by Karina Kulangara, Nancy Zhang, Ellie Corigliano, Lindsay Guerrero, Stephanie Waldroup, Dipeshkumar Jaiswal, Malinka Jansson, Supriya Shah, Debra Hanks, Jiangdian Wang, Jared Lunceford, Mary J. Savage, Jonathan Juco, Kenneth Emancipator

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Urothelial Tract Cancer

    A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Urothelial Tract Cancer by Elizabeth R. Plimack, Shilpa Gupta, Joaquim Bellmunt, Raanan Berger, B. Montgomery, Edward J. Gonzalez, Jennifer Pulini, Marisa Dolled‐Filhart, Kenneth Emancipator, Kumudu Pathiraja, Christine K. Gause, Rodolfo F. Perini, J. Cheng, Patrick O’Donnell

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases

    Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases by Jong‐Mu Sun, Wei Zhou, Yoon‐La Choi, So‐Jung Choi, Se Eun Kim, Zhen Wang, Marisa Dolled‐Filhart, Kenneth Emancipator, Dianna Wu, Russell Weiner, Dennis M. Frisman, Hong Kwan Kim, Yong Soo Choi, Young Mog Shim, Young Tae Kim

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Gastric Cancer

    A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Gastric Cancer by Kei Muro, Yung‐Jue Bang, Veena Shankaran, Ravit Geva, Daniel V.T. Catenacci, Shilpa Gupta, Joseph P. Eder, Raanan Berger, Edward J. Gonzalez, Jennifer Pulini, Assaf Ray, Marisa Dolled‐Filhart, Kenneth Emancipator, Kumudu Pathiraja, Xinxin Shu, Minori Koshiji, J. Cheng, H.C. Chung

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

    Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal by Patrick A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster, Michael J. Pishvaian, Emilie M.J. van Brummelen, Roger B. Cohen, Carlos Gomez‐Roca, Samuel Ejadi, Mark N. Stein, Emily Chan, Matteo Simonelli, Anne Morosky, Sanatan Saraf, Kenneth Emancipator, Minori Koshiji, Jaafar Bennouna

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

    Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinic... by Matteo S. Carlino, Georgina V. Long, Dirk Schadendorf, Caroline Robert, Antoni Ribas, Erika Richtig, Marta Nyakas, Christian Caglevic, Ahmed Tarhini, Christian U. Blank, Christoph Höeller, Gil Bar‐Sela, Catherine Barrow, Pascal Wolter, Haiyu Zhou, Kenneth Emancipator, Erin Jensen, Scot Ebbinghaus, Nageatte Ibrahim, Adil Daud

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

    Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial by Rina Hui, Edward B. Garon, J.W. Goldman, Natasha B. Leighl, Matthew D. Hellmann, Amita Patnaik, Leena Gandhi, Joseph P. Eder, Myung‐Ju Ahn, Leora Horn, Enriqueta Felip, Enric Carcereny, Reshma Rangwala, Gregory M. Lubiniecki, J. Zhang, Kenneth Emancipator, Charlotte Roach, Naiyer A. Rizvi

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Contribution of tumour and immune cells to <scp>PD‐L1</scp> expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from <scp>KEYNOTE</scp>‐119

    Contribution of tumour and immune cells to <scp>PD‐L1</scp> expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from <scp>KEYNOTE... by Javier Cortés, Eric P. Winer, O. N. Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K. Pruitt, Kenneth Emancipator

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)

    Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Sma... by Edward B. Garon, Leena Gandhi, Naiyer A. Rizvi, Rina Hui, Ani Sarkis Balmanoukian, Amita Patnaik, Joseph P. Eder, George Blumenshein, Charu Aggarwal, J.C. Soria, Myung‐Ju Ahn, Matthew A. Gubens, Suresh S. Ramalingam, Elizabeth A. Johnson, Hendrik‐Tobias Arkenau, Gregory M. Lubiniecki, J. Zhang, R. Rutledge, Kenneth Emancipator, Natasha B. Leighl

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

    PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project by Fred R. Hirsch, Abigail S. McElhinny, Dave Stanforth, James Ranger‐Moore, Malinka Jansson, Karina Kulangara, William D. Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa, Amita Mistry, Rasika Kalamegham, Steve Averbuch, James Novotny, Eric H. Rubin, Kenneth Emancipator, Ian McCaffery, J. Andrew Williams, Jill Walker, John Longshore, Ming‐Sound Tsao, Keith M. Kerr

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

    Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial by Roy S. Herbst, Paul Baas, Jose Luis Pérez‐Gracia, Enriqueta Felip, Dong‐Wook Kim, Ji‐Youn Han, Julian R. Molina, Jee Hyun Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Veerle Surmont, Gilberto de Castro, Marcelo Garrido, Yue Shentu, Kenneth Emancipator, Ayman Samkari, Erin Jensen, Gregory M. Lubiniecki, Edward B. Garon

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

    Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma by Adil Daud, Jedd D. Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S. Weber, Antoni Ribas, F. Stephen Hodi, Anthony M. Joshua, Richard Kefford, Peter Hersey, Richard W. Joseph, Tara C. Gangadhar, Roxana Dronca, Amita Patnaik, Hassane M. Zarour, Charlotte Roach, Grant Toland, Jared Lunceford, Xiaoyun Li, Kenneth Emancipator, Marisa Dolled‐Filhart, S. Peter Kang, Scot Ebbinghaus, Omid Hamid

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

    Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer by Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

    The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials a... by Paula I. González-Ericsson, Elisabeth Specht Stovgaard, Luz F. Sua, Emily Reisenbichler, Zuzana Kos, Jodi M. Carter, Stefan Michiels, John Le Quesne, Torsten O. Nielsen, Anne‐Vibeke Lænkholm, Stephen B. Fox, Julien Adam, Thomas John, David L. Rimm, Cecily Quinn, Dieter Peeters, Maria Vittoria Dieci, Anne Vincent‐Salomon, Ian A. Cree, Akira I. Hida, Justin M. Balko, Harry R. Haynes, Isabel Frahm, Gabriela Acosta‐Haab, Marcelo Luiz Balancin, Enrique Bellolio, Wentao Yang, Pawan Kirtani, Tomoharu Sugie, Anna Ehinger, Carlos Castaneda, Marleen Kok, Heather L. McArthur, Kalliopi P. Siziopikou, Sunil Badve, Susan Fineberg, Allen M. Gown, Giuseppe Viale, Stuart J. Schnitt, Giancarlo Pruneri, Frederique Penault‐Llorca, Stephen M. Hewitt, E. Aubrey Thompson, Kimberly H. Allison, W. Fraser Symmans, Andrew M. Bellizzi, Edi Brogi, David A. Moore, Denis Larsimont, Deborah Dillon, Alexander J. Lazar, Huang‐Chun Lien, Matthew P. Goetz, Glenn Broeckx, Khalid El Bairi, Nadia Harbeck, Ashley Cimino‐Mathews, Christos Sotiriou, Sylvia Adams, S Liu, Sibylle Loibl, I‐Chun Chen, Sunil R. Lakhani, Jonathan Juco, Carsten Denkert, Elizabeth F. Blackley, Sandra Demaria, Roberto A. Leon‐Ferre, Oleg Gluz, Dimitrios Zardavas, Kenneth Emancipator, Scott Ely, Sherene Loi, Roberto Salgado, Melinda E. Sanders

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: